According to the Council for Responsible Nutrition, a trade group for the $32 billion nutritional supplement industry, 68% of adults take dietary supplements. Further analysis shows that supplement use is more prevalent among women, the children of women that take supplements, and the elderly. Like drugs, supplements do not work the same in all patients … Continued
The Simcyp Population-based Simulator streamlines drug development through the modeling and simulation of pharmacokinetics and pharmacodynamics in virtual populations. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated platform for the prediction of drug-drug interactions and pharmacokinetic outcomes in clinical populations.
The Cardiac Safety Simulator™ (CSS) is a systems biology-driven, modeling and simulation-based platform for the assessment of the pro-arrhythmic potency of drugs, new chemical entities, and other xenobiotics within the targeted clinical population.
Antibody Drug Conjugates (ADCs) are constructed by attaching a small molecule drug to an antibody via a linker. The antibody selectively targets tumor cells and releases the cytotoxic drug within the cells to kill cancerous cells while sparing healthy tissue. Although some ADCs have been approved, many unanswered questions remain, such as drug-drug interactions (DDIs) and … Continued
Scientists developed a PBPK pregnancy model, implemented in the Simcyp Simulator and tested for its ability to simulate drug concentration changes over time.
The Simcyp Simulator improves decision-making regarding the need for clinical studies in obese subjects.
Analysis of in vitro data from whole cell systems and dissolution studies is complex, challenging and time consuming. Yet accurate data analysis and informed data interpretation early in drug development is crucial. Existing tools have mainly been developed for broader data analysis and are not specifically designed for in vitro systems. These software tools do not readily support analysis … Continued
There is a renewed surge of interest in applications of physiologically-based pharmacokinetic (PBPK) models by the pharmaceutical industry and regulatory agencies. Developing PBPK models within a systems pharmacology context allows separation of the parameters pertaining to the animal or human body (the system) from that of the drug and the study design which is essential to develop … Continued
PRINCETON, NJ – Apr. 12, 2016 – The Simcyp In Vitro (Data) Analysis (SIVA) Toolkit 2.0 assists drug development researchers with the analysis of complex in vitro studies.
In vitro dissolution testing is a critical component of drug product development programs and is often used as a surrogate for in vivo performance. Consequently, mechanistic modelling of in vitro dissolution studies and informed data interpretation early in the formulation development process is crucial. The Simcyp In Vitro (Data) Analysis (SIVA) toolkit is a standalone … Continued
